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Abstract Continued diversification and use of new psychoactive substances (NPS) across
Europe remains a public health challenge. The study describes health and social consequences
of recent NPS use as reported in a survey of marginalised, nightlife and online NPS users in the
Netherlands, Hungary, Portugal, Ireland, Germany and Poland (n = 3023). Some respondents
were unable to categorise NPS they had used. Use of ‘herbal blends’ and ‘synthetic
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cannabinoids obtained pure’ was most reported in Germany, Poland and Hungary, and use of
‘branded stimulants’ and ‘stimulants/empathogens/nootropics obtained pure’ was most re-
ported in the Netherlands. Increased heart rate and palpitation, dizziness, anxiety, horror trips
and headaches were most commonly reported acute side effects. Marginalised users reported
substantially more acute side effects, more mid- and long-term mental and physical problems,
and more social problems. Development of country-specific NPS awareness raising initiatives,
health and social service needs assessments, and targeted responses are warranted.
Keywords Novel psychoactive substance . NPS .Marginalised drug user . Online drug user .
Nightlife . Health and social consequences
The continued diffusion, diversification and use of new psychoactive substances (NPS) across
Europe remains a public health, drug policy and legal challenge (Arfken et al. 2014; Reuter and
Pardo 2017), with science, surveillance and law enforcement struggling to keep up with the
increasing range of new designer NPS marketed to circumvent legislative controls (Hillebrand
et al. 2010; Schmidt et al. 2010; Gunderson et al. 2012; Caudevilla et al. 2013; United Nations
Office on Drugs and Crime, UNODC 2013; Seely et al. 2012; Spaderna et al. 2013; Corazza et al.
2013; Brents and Prather 2014; Papaseit et al. 2014; EMCDDA2015; Caudevilla 2016; Van Hout
and Hearne 2017; Kassai et al. 2017). The UNODC and the European Union (EU) define NPS as
‘Substances of abuse, either in a pure form or a preparation, that are not controlled by the 1961
Single Convention on Narcotic Drugs or the 1971 Convention on Psychotropic Substances, but
which may pose a public health threat’ (UNODC 2013; Council of the European Union decision
2005/387/JHA 2005; Martinotti et al. 2015, 295; EMCDDA 2016). In general, NPS represent a
multitude of synthetic and natural compounds marketed as legal alternative to conventional illicit
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drugs, the most popular being cathinone derivatives, other amphetamine-type substances, and
synthetic cannabinoids, observed since 2007 (Caudevilla 2016; EMCDDA 2016). By 2015,
EMCDDA identified 101 NPS, in addition to the 450 NPS already monitored in their surveillance
systems (EMCDDA 2015). Seven categories of NPS are adopted in the scientific literature,
namely the stimulant/cathinone; GABA activating; hallucinogen, dissociative, cannabinoid,
opioid and other/unspecified/uncategorised NPS (Van Hout and Hearne 2017). Sourcing remains
an issue with ongoing availability online and offline interactions via friends and local contacts
(Lavorgna 2014, 2016; Sande 2016; Soussan and Kjellgren 2016; van Amsterdam et al. 2015;
Van Hout and Hearne 2017), despite legislative controls in street, nightlife and online markets
(McElrath and O’Neill 2011;Wood et al. 2012; EMCDDA 2015; Caudevilla 2016; Van Hout and
Hearne 2017; Reuter and Pardo 2017).
Eurobarometer surveys report that 8% of young Europeans have experience of use of NPS
(Eurobarometer 2014). Typically, NPS users are young males (Werse and Morgenstern 2012),
with several focuses regarding groups of users: These include more mature and experienced
‘psychonauts’ operating on the Surface Web and Dark Net (Soussan and Kjellgren 2014; Van
Hout and Bingham 2013a, b; Van Hout and Hearne 2017). In some countries and/or regions,
NPS use also occurs amongst early adopter drug scenes, for example gay and club dance
scenes, and student populations (Psychonaut Web Mapping Research Group 2009; Europol-
EMCDDA 2010; Dargan et al. 2010; Carhart-Harris et al. 2011; Measham et al. 2011a;
Johnston et al. 2015) and street drug users who inject (Pas 2010; Colfax et al. 2010;
Europol-EMCDDA 2010; Brauser 2012; Van Hout and Bingham 2012; Csák et al. 2013;
Van Hout 2014a; Kapitány-Fövény et al. 2015; Hearne et al. 2016; Rácz et al. 2016).
Motivations to use NPS are similar to conventional illicit drug use motives and include
curiosity, drug and sexual pleasure, sensation seeking, self-exploration, street, peer and online
availability, perceptions around value for money and legality, poor quality of available
conventional illicit drugs, preferred desired and duration of effects, and habit or dependent
use (Werse and Morgenstern 2012); Bourne et al. 2014; Soussan and Kjellgren 2016; Van
Hout 2014b; van Amsterdam et al. 2015; Van Hout and Hearne 2015; Global Drug Survey
(GDS) 2016; Schmidt et al. 2016). The engagement of NPS users and interested parties within
online drug fora for information sharing and advice around harm reduction is also increasingly
observed (Hearne and Van Hout 2016; Rosino and Linders 2015; Soussan and Kjellgren 2015,
2016; Van Hout 2014a, b; Van Buskirk et al. 2016; Van Hout and Hearne 2015, 2017).
Social and legal consequences generally include the effects of NPS use on individuals,
families, communities and the society in general. Use of NPS is associated with a range of
acute and chronic health harms which are dependent on user characteristics and vulnerabilities,
environmental characteristics, level of dosage, toxicity, route of administration and the pres-
ence of other substances. Such harms generally centre on adverse cardiovascular, respiratory
and gastro-intestinal consequences of use, transmission of blood borne viruses (HIV, Hepatitis
C), neurological and psychiatric harms (for example psychosis and suicidal ideation), depen-
dence and death (Every-Palmer 2010; Hadlock et al. 2011; Maan and D’Souza 2011; Lusthof
et al. 2011; Werse and Morgenstern 2012; Kasick et al. 2012; Grandy 2012; Seely et al. 2012;
Gunderson et al. 2012; King and Nutt 2014; Abdulrahim et al. 2015; Van Hout 2016).
We report here on the declared acute and chronic health consequences of NPS use, and
incurred social and legal problems as reported by the three groups of identified European NPS
users, namely, socially marginalised users who are high risk drug users often unemployed,
homeless and/or in care; nightlife users who are recreational drug users frequenting clubs,
raves and/or festivals often in education and/or employed; and users active on the Internet and
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carrying out their NPS activity in online communities known as drug fora. The aim of the
study was to describe health, social and legal consequences of NPS use as reported by NPS
users resident in these six European countries. The research questions centred on investigating
if there are associations of certain problems with groups of NPS users; whether there are
differences between countries within these groups; and what associations occur in current use
of certain categories of NPS.
Methods
This study was undertaken within the remit of a transnational and interdisciplinary EU funded
research project undertaken by researchers from different scientific disciplines in six EU-
countries: Germany, Hungary, Ireland, the Netherlands, Poland and Portugal. A survey was
designed based on extensive literature reviewing, country reports and expert consultations in
each country, and which investigated user demographic characteristics, prevalence and patterns
of use of illicit drugs; prevalence and patterns of NPS use; and reported health and social
problems associated with use of NPS. Information was gathered on the use of seven categories
of NPS: ‘herbal blends (e.g. BSpice^)’; ‘synthetic cannabinoids (obtained pure)’; ‘branded
stimulants (e.g. Bbath salts^)’; ‘stimulants/empathogens/nootropics (obtained pure, e.g.
mephedrone, MDPV, a-PVP)’; ‘psychedelics (e.g. NBOMe-x, 2C-x’); ‘dissociatives (e.g.
methoxetamine)’; and ‘other’. The questionnaire was developed in English and translated into
the other languages in this project. To guarantee comparability, translation was done back and
forth (from/into English).
Fieldwork occurred in the first 10 months of 2016. Eligibility criteria for the survey were
(1) recent NPS use (at least once in the past 12 months), (2) resident of the participating
countries and (3) 18 years or older. A targeted sampling methodology was chosen to reach
NPS users in each of the three groups in the six participating countries:
1. Socially marginalised users were recruited face-to-face in the street, at or through user
organisations and care facilities (e.g. low threshold facilities, consumption rooms) and
through snowball sampling. Respondents were asked to either self-complete a pen-and-
paper questionnaire, have a fieldworker read out the questions and record their answers, or
complete an online questionnaire to which they were referred by a flyer containing a link
and an individual code. In most cases, pen-and-paper questionnaires were interviewer-
administered.
2. Users in night life were recruited face-to-face on-site at clubs, raves and festivals and
through snowball sampling. Respondents were given the choice to self-complete either the
pen-and-paper or online questionnaire.
3. Users in online communities were recruited by actively promoting the survey on internet
fora and other online resources. Users in online communities were only given access to the
online questionnaire.
The data was screened/cross-checked for errors and analysed using SPSS V.24. Analysis
was conducted using anonymised data and involved descriptive statistics, including frequen-
cies and percentages. Statistical tests included chi-square tests to assess differences in cate-
gorical data as well as ANOVA for mean comparison tests. Multivariate binary regression
analyses were performed to determine which factors were associated with acute unpleasant
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side effects, mid- or long-term problems and social problems. In all statistical analyses, a two-
sided significance level of 5% was used.
Respondents were asked about their use of NPS as it related to the seven categories; ‘herbal
blends’; ‘synthetic cannabinoids obtained pure’; ‘branded stimulants’; ‘stimulants/
empathogens/nootropics obtained pure’; ‘psychedelics’; ‘dissociatives’ and ‘other’. The sur-
vey responses revealed that some respondents were unable to categorise NPS they had used.
This was especially evident in the categories of ‘herbal blends’ and ‘synthetic cannabinoids
obtained pure’, and ‘branded stimulants’ and ‘stimulants/empathogens/nootropics obtained
pure’. Names of NPS were not always entered under their proper categories; respondents were
unaware of active ingredients and names of NPS they had used. For this reason, for reporting
purposes, these categories were combined.
Results
Three thousand five hundred three respondents were recruited, with 260 excluded as per
eligibility criteria (residency/below 18 years). Of the remaining 3243 respondents, 212
were excluded because they either reported not using any NPS in the past 12 months
(189/212), they answered or obviously answered the detailed questions on prevalence for
non-NPS substances only, or answered negatively to the specific NPS categories. Eight
further respondents were removed due to angry, incoherent or irrelevant responses in the
open-ended text boxes.
Respondent Profile
The final data set for analysis was 3023 recent NPS users. See Table 1. The online community
sample was the largest (2110) and the marginalised sample was the smallest (266) across the
six countries. Recruitment complexities such as low reporting of recent NPS use among certain
categories of drug users in different countries was particularly evident in the marginalised
respondents from the Netherlands and Portugal, and night life respondents from Ireland, with
less than 10 respondents.
In terms of examining all three samples across the six countries, more than three
thirds of respondents were male (marginalised 71.7%, night life 67.9%, online 68.0%).
See Table 2. The online community respondents were youngest with an average age of
Table 1 Sample countries
Marginalised Night life Online Total
Sample
Germany 23 98 542 663
Hungary 101 15 156 272
Ireland 48 3 11 62
The Netherlands 1 189 1000 1190
Poland 86 172 338 596
Portugal 7 170 63 240
Total 266 647 2110 3023
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23.6 years, with 70.3% falling within the 18–24 age group. The night life respondents
were on average 25.7 years. The marginalised respondents were oldest across all
countries with an average of 33.5 years. In terms of location, the majority of
marginalised and night life respondents were resident in large towns with more than
100.000 inhabitants (86.8/68.5%, respectively). Most of the night life and online com-
munity respondents lived either with their parents or family (27.6 and 44.1%), or in a
rented accommodation (47.1 and 39.6%). A substantial proportion of the marginalised
respondents in contrast reported living in homeless accommodations or hostels (32.3%)
or other living arrangements (12.3%), including living on the streets (sleeping rough).
Both night life and online respondents reported higher levels of education. Many had
completed a secondary level education (46.2/56.2%, respectively), were studying for a
higher degree (28.6/43.7%, respectively), or reported having a college or university
diploma (37.3/28.6%, respectively). The majority of the marginalised respondents had
completed none or just primary education (55.2%), with a minority being students
(3.1%). The majority also were unemployed and/or living on benefits (75.7%).
Table 2 Respondent profile
Marginalised
n = 266
Night life
n = 647
Online
n = 2.110
p
Gender
Male 71.7% 67.9% 68.0% .457
Female 28.3% 21.1% 32.0%
Age
18–24 years 17.4% 50.1% 70.3% .000
25–34 years 36.7% 41.7% 23.7%
35–44 years 35.9% 7.6% 5.1%
45 years and older 10.0% 0.6% 1.0%
Average (sd) 33.5 (8.7) 25.7 (5.9) 23.6 (5.8) .000
Residence
Small town (pop. < 50.000) 6.1% 17.3% 41.2% .000
Medium town (pop. 50.000–100.000) 8.1% 14.0% 17.0%
Large town (pop. > 100.000) 85.8% 68.6% 41.8%
Living arrangements
Own home 6.9% 20.8% 14.5% .000
Rent apartment or room 14.6% 47.1% 39.6%
Parents/family 16.5% 27.6% 44.1%
Friend’s home 9.6% 3.4% 1.1%
Residential care 7.7% 0.6% 0.2%
Homeless accommodation/hostel 32.3% 0.3% 0.2%
Other 12.3% 0.2% 0.4%
Level of education
None 7.7% 0.3% 0.6% .000
Primary school 47.5% 16.9% 12.8%
Secondary school 37.9% 45.2% 56.2%
College/university 5.7% 37.3% 28.5%
Doctor’s degree, PhD, etc. 1.1% 0.3% 1.9%
Employment
Student 3.1% 28.6% 43.7% .000
Full-time worker 3.5% 39.0% 30.6%
Part-time or casual worker 9.4% 12.0% 11.7%
Self-employed 5.9% 9.3% 5.4%
Unemployed/benefits 75.7% 10.8% 8.1%
Other 2.4% 0.3% 0.5%
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Use of NPS
In terms of categories of NPS used, when comparing the six countries, use of ‘herbal blends’
and ‘synthetic cannabinoids obtained pure’ was most reported in Germany, Poland and
Hungary, and use of ‘branded stimulants’ and ‘stimulants/empathogens/nootropics obtained
pure’ was most reported in the Netherlands. See Table 3. Recent use of ‘psychedelics’ was
most commonly reported by respondents from Portugal and Germany. To some degree, these
results reflect the different sizes of subsamples in different countries, e.g. with Portuguese
respondents mainly coming from nightlife settings, or Hungarian respondents who often were
marginalised users.
When looking at frequent use of particular NPS categories, marginalised users were much
more likely to show such patterns than the other two groups: 17.9% of the marginalised
respondents reported daily herbal blend/synthetic cannabinoid use, compared to 1.2% of the
night life and 2.8% of the online respondents. The respective figures for daily stimulant NPS
use are 18.2% (marginalised), 0.3% (night life) and 1.0% (online). In terms of route of
administration, the majority of marginalised respondents reported life time intravenous use
(74.4%), compared to 3.6% of night life and 4.9% of online respondents. These observations
were also reflected in the modes of NPS administration: while 51.1% of the marginalised users
mentioned injection as the preferred mode of administration, only 0.8% of the other groups did
so. Overall, swallowing was the most prevalent mode (online 61.6, night life 45.6,
marginalised 2.6%).
Side Effects of NPS Use and Associated Health and Social Problems
Within all three subsamples, the majority of recent NPS users had experienced acute unpleas-
ant side effects after NPS use. See Table 4. In terms of reporting of acute side effects,
experiences of increased heart rate and palpitation, dizziness, anxiety and horror trips and
headaches were reported as most common across all three categories. The proportion who had
experienced these effects was substantially larger in the marginalised sample (85.3%), than in
the night life and online community samples (58.8 and 51.0%). When looking at the separate
side effects, there are significant differences between the three groups in every symptom, with
Table 3 Life time use of NPS categories
Herbal blends and/or
pure synthetic cannabi-
noids
Branded and/or
pure stimulants
Psychedelics Dissociatives Other NPS
Sample
Marginalised 73.3% .000 85.0% .000 22.2% .000 22.6% .896 10.9% .000
Night life 55.8% 73.1% 56.7% 21.6% 13.0%
Online community 46.2% 79.9% 51.3% 21.3% 34.3%
Country
Germany 63.0% .000 50.1% .000 75.9% .000 33.9% .000 37.6% .000
Hungary 89.7% 79.4% 26.1% 28.3% 32.7%
Ireland 48.4% 88.7% 21.0% 11.3% 17.7%
The Netherlands 16.6% 96.7% 40.0% 10.3% 21.8%
Poland 81.5% 82.9% 40.3% 27.9% 30.4%
Portugal 64.2% 57.1% 85.8% 21.7% 19.6%
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mostly much higher proportions of marginalised users reporting these effects. When compar-
ing night life users and online community users, night life users reported more unpleasant
effects, especially head and stomach aches and dizziness. However, in all categories,
marginalised users show much higher rates than the two other groups. Increased heart rate
or palpitation was the most reported side effect in all three samples.
Marginalised users when compared to the other two categories reported also more mid- and
long-term mental and physical problems (addiction withdrawals and craving, weight loss,
depression and paranoid disorders) (70.3%) than the night life and online community samples
(28.4 and 30.9%). In terms of mid- to long-term consequences of use, addiction withdrawals
and craving were reported by almost half of marginalised users along with weight loss,
depression and paranoid disorders. In comparison, such experiences were reported by a
minority of online and nightlife users. Across all three categories, however, paranoid disorders,
depression, weight loss and symptoms of addiction were most common. Marginalised users
also reported more social problems as a consequence of NPS use than the other groups of users
(mainly conflicts with partner or family, problems with housing and legal problems) (69.1
versus 22.1 and 22.2%). Low proportions of online and nightlife users reported social or legal
problems. If any, respondents from these groups were most likely to report conflicts with
Table 4 Side effects and problems from NPS use among marginalised, night life and online NPS users
Marginalised
n = 266
Night life
n = 647
Online
n = 2.110
p
Acute unpleasant side effects
Increased heart rate/palpitation 57.5% 37.7% 35.8% .000
Headaches 51.5% 26.6% 18.9% .000
Stomach ache 38.0% 18.2% 12.8% .000
Dizziness 44.7% 29.2% 20.7% .000
Muscle cramps 33.1% 15.0% 12.7% .000
Loss of consciousness/coma 23.3% 9.9% 6.7% .000
Anxiety/horror trips 47.7% 25.5% 21.2% .000
Shortness of breath 36.8% 16.0% 13.1% .000
Hyperthermia 33.5% 17.8% 17.7% .000
Aggression/violence 35.7% 11.1% 4.9% .000
Paranoia 52.3% 21.9% 17.7% .000
Other 4.1% 4.9% 6.3% .221
Total 85.3% 58.8% 51.0% .000
Mid- or long-term problems
Addiction/withdrawal/craving 46.2% 7.4% 12.1% .000
Depression 43.2% 13.6% 14.5% .000
Paranoid disorders 38.7% 9.6% 8.2% .000
Weight loss 46.2% 9.6% 9.5% .000
Harms of injecting 26.7% 0.5% 0.8% .000
Other mental problems 15.8% 6.3% 8.6% .000
Other physical problems 12.4% 4.2% 6.4% .000
Total 70.3% 28.4% 30.9% .000
Social problems
Conflict at school, university, etc. 6.8% 4.3% 4.7% .277
Conflict at work 12.0% 5.6% 3.8% .000
Conflicts with partner or family 45.9% 13.6% 12.8% .000
Problems regarding housing 42.5% 3.7% 3.1% .000
Legal problems 35.7% 6.2% 5.5% .000
Other 3.0% 1.1% 1.7% .117
Total 69.1% 22.1% 22.2% .000
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partner or family, while, in contrast to the marginalised users, problems regarding housing and
legal problems were relevant for very few nightlife and online respondents. See Table 4.
The proportions of different problems experienced by the respondents vary substantially by
country of residence. See Table 5. Irish, Hungarian and Polish respondents were generally
much more likely to report problems than Dutch or Portuguese users, with German users
ranking in between. When looking at different types of problems, mid- and long-term
problems, including social problems, were most prevalent in Ireland and Hungary. However,
to a substantial degree, these differences reflect the varying distribution of user groups in the
national samples (see Table 1 and the later ‘regression analysis’). When looking at side effects
and problems among those who have experience in the use of different NPS categories, some
differences were evident. See Table 5; no comparative statistical analysis given here because of
overlapping groups. Overall, these results show a consistent picture that dissociatives and
synthetic cannabinoids are the substances that are mostly associated to such problems.
Interestingly, this is true for nearly all kinds of problems, no matter if physical, mental or
social, and no matter if these are long-term (including addiction and withdrawal) or acute
effects.
Regression Analyses
Results show that negative experiences from NPS use are related to both type of user, country
and categories of NPS used. Multivariate binary regression analyses was conducted to
determine which of these three factors was most strongly associated with acute unpleasant
side effects, mid- or long-term problems, and social problems. For type of user, marginalised
users were chosen as the reference category, as they clearly deviate from the other two
subsamples. For country, Ireland was chosen as the reference category, because respondents
from the Irish sample most often reported negative experiences. Life time use of NPS
categories were entered as dummy variables (1 = yes, 0 = no). See Table 6. Results indicate
that online community NPS users—but not night life users—have less often experienced acute
unpleasant side effects from NPS use than marginalised users, that Irish NPS users have
experienced more side effects than NPS users from other countries, and that life time use of
Table 5 Side effects and problems from NPS use per country and per lifetime use
Acute unpleasant
side effects
Mid- or long-term
problems
Social
problems
Country
Germany 62.2% .000 26.9% .000 22.9% .000
Hungary 78.7% 63.7% 60.4%
Ireland 95.2% 70.5% 74.6%
The Netherlands 35.7% 24.7% 9.5%
Poland 78.5% 49.3% 47.2%
Portugal 42.2% 15.5% 15.2%
Life time use
Herbal blends and/or pure synthetic cannabinoids 69.7% 42.6% 38.6%
Branded and/or pure stimulants 56.4% 37.2% 28.8%
Psychedelics 56.8% 30.9% 25.6%
Dissociatives 72.1% 44.5% 39.8%
Other NPS 61.0% 39.4% 34.4%
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herbal blends and/or pure synthetic cannabinoids, branded and/or pure stimulants, and disso-
ciative NPS—but not psychedelic or other NPS is associated with unpleasant side effects.
These associations between group, country and category of NPS used are independent from
each other. Differences between countries, for instance, exist regardless of group of NPS users
or life time use of categories of NPS. To illustrate this: among Irish marginalised life time users
of stimulant NPS, 97.8% have ever experienced acute unpleasant side effects of NPS use,
while among Hungarian marginalised life time users of stimulant NPS, this proportion was
significantly smaller at 80.5% (chi-square = 7.553, p = .006). Thus, while the large differences
between countries mainly reflect the varying distribution of user groups, there are also
significant differences in the same user group by country. As for mid- or long-term problems,
these are associated with being a marginalised user, living in Ireland, Hungary or Poland, and
life time use of herbal blends and/or pure synthetic cannabinoids, branded and/or pure
stimulants, and dissociative NPS. Social problems are associated with being a marginalised
user, living in Ireland or Hungary, and life time use of herbal blends and/or pure synthetic
cannabinoids, branded and/or pure stimulants, dissociative NPS, and other NPS.
Discussion
This study was undertaken within the remit of a transnational and interdisciplinary EU funded
research project undertaken by researchers from different scientific disciplines in six EU-
countries: Germany, Hungary, Ireland, the Netherlands, Poland and Portugal. Limitations of
the prevalence and other data centre on the varied composition of country samples. Key
findings centre on the particular trends visible in NPS use across countries, and the three
identified NPS user groups (marginalised, nightlife and online). Most notable and similar to
other research (Measham et al. 2011a; Van Hout 2016) was that the concept of NPS was not
Table 6 Regression analysis of side effects and problems from NPS use across groups and lifetime use of NPS
Acute unpleasant
side effects
Mid- or long-term
problems
Social problems
B S.E. p B S.E. p B S.E. p
Marginalised (reference category)
Night life − .309 .220 .159 − .951 .187 .000 − 1.076 .192 .000
Online community − .683 .207 .001 − .986 .172 .000 − 1.139 .174 .000
Ireland (reference category)
Germany − 2.115 .619 .001 − 1.118 .329 .001 − 1.632 .349 .000
Hungary − 1.702 .622 .006 − .095 .330 .773 − .510 .348 .142
The Netherlands − 3.048 .616 .000 − 1.190 .323 .000 − 2.485 .348 .000
Poland − 1.634 .616 .008 − .485 .319 .129 − .820 .338 .015
Portugal − 3.181 .630 .000 − 1.803 .369 .000 − 2.125 .390 .000
Life time use of herbal blends and/or pure
synthetic cannabinoids
.556 .099 .000 .430 .106 .000 .596 .121 .000
Life time use of branded and/or pure
stimulants
.460 .115 .000 .728 .126 .000 .799 .135 .000
Life time use of psychedelics .094 .095 .325 − .087 .101 .389 .104 .119 .383
Life time use of dissociatives .473 .118 .000 .337 .118 .004 .265 .129 .039
Life time use of other NPS − .030 .101 .763 .181 .102 .077 .377 .115 .001
Constant 2.453 .607 .000 .222 .316 .484 .275 .336 .414
Nagelkerke R2 .236 .184 .309
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always clear at consumer level, with some users not clear on what NPS category they had used,
and were unaware of the active ingredients. Additional limitations centred on the general
nature of questions of negative experiences when using NPS which could have biased
associations when multiple NPS categories were used within poly drug using episodes. We
also recognise that respondents may have been recollecting negative experiences and may
have since ceased using that particular NPS.
Proportions of marginalised users were larger in samples of Hungary and Ireland, while the
Portuguese sample consisted mainly of night life users and German and Dutch respondents
mainly of online community users. Poland was the only country with a more even distribution
of user groups. However, regardless of sample composition, several clear differences in NPS
use were evident. In terms of profile, demographic trends are similar to previous monitoring of
NPS (Europol-EMCDDA 2010; Carhart-Harris et al. 2011; Measham et al. 2011b; Werse and
Morgenstern 2012; Eurobarometer 2014; Johnston et al. 2015; Martinotti et al. 2015; Global
Drug Survey 2016). Recent NPS users in all countries are predominantly male (less than one
third female).
In general, recent users of all categories of NPS are mainly young adults aged 18–24 years.
The online community sample was the youngest with the majority falling within the 18–24 age
group. We know that the internet and social media fuels the marketing, popularity and sale of
NPS (Orsolini et al. 2016; Lavorgna 2016) with younger drug users active on online websites
(Móró and Rácz 2013; Rosino and Linders 2015; Soussan and Kjellgren 2014, 2016; Van
Hout 2014a, b; Van Buskirk et al. 2016; Hearne and Van Hout 2016; Bilgrei 2016; Tzanetakis
et al. 2016; Van Hout and Hearne 2015, 2017). Night life users were somewhat older: between
18 and 35 years (average 25.7 years). Most night life users reside in large towns, but online
community users often live in small and medium-sized towns. Levels of education are high
among both night life and online community users. Marginalised users of NPS were older than
the other two samples (average 33.5 years), and predominantly found in large towns, have had
little education and were often unemployed.
Use of ‘herbal blends’ and ‘synthetic cannabinoids obtained pure’ was most prevalent in
Germany, Poland and Hungary, and least prevalent in the Netherlands. In contrast, use of
‘branded stimulants’ and ‘stimulants/empathogens/nootropics obtained pure’ was most prev-
alent in the Netherlands, and least popular in Portugal. Diffusion of both categories has been
reported elsewhere (Arfken et al. 2014). The Portuguese and German samples are distin-
guished by high levels of ‘psychedelic’ NPS use, and ‘dissociative’ and ‘other’ NPS were
highest in Germany and lowest in Ireland. In terms of most popular NPS used in these
countries, all three categories of NPS users reported majority use of stimulants. This reflects
trend data which reports on high demand for synthetic stimulants in Europe due to displace-
ment from traditional drugs such as amphetamine, MDMA and cocaine. With regard to the
number of different substances detected in previous years, synthetic cathinones are the second
largest group of NPS (EMCDDA 2015). Similar trends are described on contemporary drug
fora on the Surface Web (Van Hout 2014b; Van Hout and Hearne 2015; Sande 2016; Hearne
and Van Hout 2016).
Similar to Hearne and Van Hout (2016), marginalised NPS users also differed from night
life and online community users in terms of reporting a higher prevalence of use of herbal
blends and/or synthetic cannabinoids and stimulants, a lower prevalence of psychedelic NPS
use, and had less awareness of the active synthetic ingredients in herbal blends. Online
community users distinguish from both marginalised and night life users by relatively high
levels of benzodiazepine class NPS. This has also been observed in online NPS users active on
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the Darknet (Van Hout and Hearne 2017) and as popular trend in online pharmacies (Littlejohn
et al. 2005). There was no difference between NPS user categories in terms of dissociative
NPS. Route of administration differed between groups, with marginalised users using com-
monly via injection, a mode that was used by barely anyone from the other groups. A history
of intravenous drug use was relatively prevalent among users of ‘herbal blends’, ‘synthetic
cannabinoids obtained pure’ and ‘dissociatives’ NPS.
Dissociatives and synthetic cannabinoids are the substances that are mostly associated to
health and social problems. It is important to note that poly use of NPS compounds (sequential
and concurrent) and NPS with conventional illicit drugs is common and can exacerbate such
acute effects (Van Hout and Hearne 2017). That said, the reported acute side effects support
those described in the literature (Stepens et al. 2008; Auwärter et al. 2009; Every-Palmer 2010;
Hadlock et al. 2011; Maan and D’Souza 2011; Dargan et al. 2010, Vearrier and Osterhoudt
2010; Lusthof et al. 2011; Kasick et al. 2012; Grandy 2012; Seely et al. 2012; Gunderson et al.
2012; Tung et al. 2012; Werse and Morgenstern 2012; King and Nutt 2014; Soussan and
Kjellgren 2015, 2016; Van Hout 2014b; Abdulrahim et al. 2015; Van Hout 2016; Bassir et al.
2016; Van Hout and Hearne 2016, 2017) and include experiences of increased heart
rate/palpitation, dizziness, anxiety/horror trips and headaches as the most common symptoms
across all three categories. Life time use of herbal blends and/or pure synthetic cannabinoids,
branded and/or pure stimulants, and dissociative NPS, but not psychedelic or other NPS is
associated with such unpleasant side effects. Online community NPS users, but not night life
users, reported less often experiences of acute unpleasant side effects from NPS use than
marginalised users. Generally, the relatively high rates of acute side effects experienced by
users with experiences in synthetic cannabis use are in line with prior observations that users of
such substances report more, and quite divergent, negative side effects than users of other NPS
(Werse and Egger 2016), as well as toxicological research that assesses such substances as
much more risky than cannabis with regard to overdose and other physical symptoms
(Moosmann and Auwärter 2016). Further comparative research is needed to assess whether
symptoms experienced by users of particular NPS categories differ from the symptoms
experienced after the use of common illicit drugs of the same class of substances.
Marginalised users not only reported substantially more acute and unpleasant side effects
than other respondents, but reported particularly much more mid- and long-term mental and
physical problems (addiction withdrawals and craving, weight loss, depression and paranoid
disorders) and social problems (conflict with partner or family, problems with housing and
legal problems) as a consequence of NPS use. These results could be expected, given the risk
behaviours associated with injecting and dependent drug use, as well as the precarious social
situation of drug users who are marginalised by definition. Mid- and long-term problems are
associated with being a marginalised user, living in Ireland, Hungary or Poland, and life time
use of herbal blends and/or pure synthetic cannabinoids, branded and/or pure stimulants, and
dissociative NPS. Addiction withdrawals and craving were reported by almost half of
marginalised users along with weight loss, depression and paranoid disorders. Currently, there
is a limited demand for specialist NPS treatment in Europe, despite some Member States
identifying a need for such clinical and treatment services (EMCDDA 2016). Social problems
are associated with being a marginalised user, living in Ireland or Hungary, and life time use of
herbal blends and/or pure synthetic cannabinoids, branded and/or pure stimulants, dissociative
NPS, and other NPS. Low proportions of online and nightlife users reported social or legal
problems in terms of conflict at school or university, with partners or family, or with housing.
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Conclusion
The study is illustrative of the need for continued surveillance and monitoring of NPS trends
across Europe. The development of country-specific information resources, awareness raising
and prevention initiatives particularly around the contents of popular NPS is warranted.
Appropriate clinical responses to acute side effects and mid- to long-term problems associated
with NPS use across the three NPS user groups are needed, along with enhanced social service
supports for NPS user groups experiencing associated problems. Country-specific initiatives in
response to user trends should include the regular training of health and social care profes-
sionals, health and social service needs assessments, and targeted service responses to reduce
incurred harms.
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